Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers

Lantern, in collaboration with academic research partners, has advanced the development, synthesis, and preclinical proof-of-concept of a novel, highly potent, cryptophycin-based ADC.



The...

Related Keywords

,Kishor Bhatia ,Linkedin ,Securities Exchange ,Nasdaq ,Bielefeld University ,Lantern Pharma Inc ,Exchange Commission On ,Lantern Pharma ,Business Wire ,Chief Scientific Officer ,Securities Act ,Securities Exchange Act ,Risk Factors ,Annual Report ,Exchange Commission ,Markets ,